Risk Of New Suicidal Thoughts During Antidepressant Treatment Has Genetic Component, New AJP Study Shows
DNA samples from patients in the federally funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial have revealed two genetic markers that appear to be associated with the emergence of suicidal thoughts during treatment with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. The findings strongly suggest a genetic basis underlying the rare emergence of suicidal thoughts associated with taking an SSRI.
